

Claim 1 (Currently Amended). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that has at least 94% amphotericin B and 4% or less of impurity products, and a pharmaceutically effective carrier;
and

administering a therapeutically effective amount of a said composition to a subject in need thereof comprising amphotericin B and a pharmaceutically acceptable carrier, wherein the amphotericin B is substantially pure.

Claim 2 (Currently Amended). The method of claim 1, wherein the amphotericin B is greater than present in an amount greater than about 96% pure.

Claim 3 (Currently Amended). The method of claim 1, wherein the amphotericin B is greater than present in an amount greater than about 98% pure.

Claim 4 (Original). The method of claim 1, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 5 (Original). The method of claim 1, wherein the administering step is intravenous.

Claim 6 (Currently Amended). A pharmaceutical composition, comprising:

an active ingredient that has at least 94% amphotericin B and 4% or less of impurity products, substantially pure amphotericin B and a pharmaceutically acceptable carrier.

Claim 7 (Currently Amended). The composition of claim 6, wherein the amphotericin B is greater than present in an amount greater than about 96% pure.

Claim 8 (Currently Amended). The composition of claim 6, wherein the amphotericin B is greater than present in an amount greater than about 98% pure.


Claims 9-16 (canceled).

Claim 17 (New). The method of claim 1, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 18 (New). The composition of claim 6, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 19 (New). A pharmaceutical composition that comprises:

an active ingredient that is at least 96% w/w of a compound of the following formula:



and a pharmaceutically acceptable carrier.

Claim 20 (New). The composition of claim 19, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 21 (New). The composition of claim 19, comprising less than 4% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound.